Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Income towards Parent Company (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Income towards Parent Company data on record, last reported at -$5.7 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 75.91% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$23.4 million, up 73.43%, while the annual FY2025 figure was -$23.4 million, 73.43% up from the prior year.
  • Income towards Parent Company reached -$5.7 million in Q4 2025 per MIRM's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $57.3 million in Q4 2021 and bottomed at -$74.0 million in Q2 2023.
  • Average Income towards Parent Company over 5 years is -$24.7 million, with a median of -$26.1 million recorded in 2022.
  • Peak YoY movement for Income towards Parent Company: skyrocketed 253.97% in 2021, then crashed 175.01% in 2023.
  • A 5-year view of Income towards Parent Company shows it stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then soared by 75.91% to -$5.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$5.7 million in Q4 2025, $2.9 million in Q3 2025, and -$5.9 million in Q2 2025.